Objective:

To explore the role of gut microbiota in the pathogenesis of Guillain-Barré Syndrome (GBS) and investigate potential microbial metabolites and treatment strategies, highlighting the significance of microbiota in modulating immune responses.

Key Findings:

• Gut microbiota plays a crucial role in modulating immune responses relevant to GBS pathogenesis, with dysbiosis leading to increased systemic inflammation and autoantibody production.
• Specific microbial taxa may serve as biomarkers for GBS susceptibility and progression, indicating potential diagnostic pathways.
• Microbiota-targeted therapies show promise in restoring immune balance and supporting recovery, suggesting new avenues for treatment.

Interpretation:

The gut microbiota significantly influences the immune mechanisms involved in GBS, suggesting that microbiome modulation could be a viable therapeutic strategy with potential implications for clinical practice.

Limitations:

• Limited direct microbiome studies in GBS patients, highlighting the need for more comprehensive research.
• Heterogeneity in existing studies regarding microbiota composition and disease associations, necessitating standardized methodologies.
• Need for further research to validate findings and establish causal relationships, particularly in diverse populations.

Conclusion:

Future research integrating metagenomic and immunologic profiling is essential to validate the role of gut microbiota in GBS and develop personalized microbiota-based interventions, underscoring the urgency of this research.